Halda Therapeutics Receives FDA Fast Track Designation for HLD-0915 for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Halda Therapeutics announced that the US FDA granted Fast Track designation to HLD-0915, the company’s lead development candidate, for the treatment of patients with mCRPC.